Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03115333 · ClinicalTrials.gov registry record · NA
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
A NA study of Recurrent Glioblastoma and Gliosarcoma, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 146
- Enrollment target
- 20
- Study locations
NCT03115333: Active NA study of Recurrent Glioblastoma and Gliosarcoma, sponsored by ECOG-ACRIN Cancer Research Group.
NCT03115333 is a NA study of Recurrent Glioblastoma and Gliosarcoma that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 146 participants, above the 67-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (118% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03115333, a NA study of Recurrent Glioblastoma and Gliosarcoma, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 146 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.
Primary Outcome
Will determine whether binary changes (increase vs. decrease) in rCBV is associated with OS. Kaplan-Meier survival curves will be generated for both the increased and the decreased rCBV groups. The median survival time of both groups will be estimated and compared with a two-sided log rank test. Univariate Cox proportional hazards model will be used to test the association between changes in rCBV from baseline to 2 weeks and OS or PFS.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Study Locations (20)
Florida
- Boca Raton Regional Hospital - Boca Raton
- Baptist MD Anderson Cancer Center - Jacksonville
- Mayo Clinic in Florida - Jacksonville
- Moffitt Cancer Center-International Plaza - Tampa
- Moffitt Cancer Center - McKinley Campus - Tampa
- Moffitt Cancer Center - Tampa
California
- Eden Hospital Medical Center - Castro Valley
- Loma Linda University Medical Center - Loma Linda
- USC / Norris Comprehensive Cancer Center - Los Angeles
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- VA Palo Alto Health Care System - Palo Alto
Arizona
- Saint Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Northside Hospital - Atlanta
- Northside Hospital-Forsyth - Cumming
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
- IU Health Methodist Hospital - Indianapolis
Kentucky
- Baptist Health Lexington - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2017-07-25 |
| Est. Completion | 2027-05-07 |
| Phase | NA |
What the registry record for NCT03115333 still lists
NCT03115333 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, above the 67-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (118% higher).
The record links to 2 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging is the first listed.
NCT03115333 names 20 study sites across 6 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03115333 about?
NCT03115333 is a clinical study titled "DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma". This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blo...
What is the current status of trial NCT03115333?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 146 participants. The study started on 2017-07-25. Estimated completion is 2027-05-07.
What conditions does trial NCT03115333 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Gliosarcoma.
What interventions are being tested in trial NCT03115333?
The interventions under investigation include: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03115333?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03115333 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03115333's enrollment target sits among peer trials
146 6th of 62 higher than 57 of 62 other Recurrent Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
RECRUITING · NA
-
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
RECRUITING · NA
-
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
RECRUITING · NA
-
Mathematical Model-Adapted Radiation In Glioblastoma
COMPLETED · NA
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI